Patient characteristics
| . | Total . | Failed . | Successful . | P value . |
|---|---|---|---|---|
| N = 154 . | n = 13 . | n = 141 . | ||
| Age at apheresis, y (range) | 63 (36-76) | 58 (44-71) | 63 (36-76) | .116 |
| Sex | 1.000 | |||
| Male | 86 (55.8%) | 7 (53.8%) | 79 (56.0%) | |
| Female | 68 (44.2%) | 6 (46.2%) | 62 (44.0%) | |
| M protein subclass | .468 | |||
| IgG | 80 (51.9%) | 7 (53.8%) | 73 (51.8%) | |
| IgA | 31 (20.1%) | 1 (7.7%) | 30 (21.3%) | |
| BJP | 41 (26.6%) | 5 (38.5%) | 36 (25.5%) | |
| Nonsecreting | 1 (0.6%) | 0 (0.0%) | 1 (0.7%) | |
| ISS at diagnosis | .581 | |||
| I | 41 (26.6%) | 2 (15.4%) | 39 (27.7%) | |
| II | 52 (33.8%) | 5 (38.5%) | 47 (33.3%) | |
| III | 43 (27.9%) | 6 (46.2%) | 37 (26.2%) | |
| Deletion 17p at diagnosis∗ | 26 (16.9%) | 5 (38.5%) | 21 (14.9%) | .031† |
| t(4;14) (IGH-FGFR3) at diagnosis∗ | 27 (17.5%) | 2 (15.4%) | 25 (17.7%) | 1.000 |
| t(14;16) (IGH-MAF) at diagnosis∗ | 5 (3.2%) | 0 (0.0%) | 5 (3.5%) | 1.000 |
| Gain 1q at diagnosis∗ | 28 (18.2%) | 4 (30.8%) | 24 (17.0%) | .234 |
| Disease status at apheresis | .073 | |||
| CR | 1 (0.6%) | 1 (7.7%) | 0 (0.0%) | |
| PR | 20 (13.0%) | 1 (7.7%) | 19 (13.5%) | |
| SD | 22 (14.3%) | 1 (7.7%) | 21 (14.9%) | |
| PD | 101 (65.6%) | 8 (61.5%) | 93 (66.0%) | |
| Time from diagnosis to apheresis, mo | 74.7 (8.2-364.7) | 77.5 (23.7-139.0) | 74.3 (8.2-364.7) | .637 |
| Number of chemotherapy lines before apheresis | 6 (2-13) | 6 (4-12) | 5 (2-13) | .008† |
| Time from last chemotherapy to apheresis, d | 35 (5-770) | 45 (18-770) | 34 (5-676) | .213 |
| History of ASCT | .442 | |||
| No | 23 (14.9%) | 1 (7.7%) | 22 (15.6%) | |
| Once | 96 (62.3%) | 7 (53.8%) | 89 (63.1%) | |
| ≥2 | 35 (22.7%) | 5 (38.5%) | 30 (21.3%) | |
| Time from last ASCT to apheresis, mo | 48.7 (2.4-178.4) | 23.2 (7.2-125.1) | 53.2 (2.4-178.4) | .200 |
| IMiDs in last regimen | 85 (55.2%) | 9 (69.2%) | 76 (53.9%) | .386 |
| Time from last IMiDs to apheresis, mo | 1.2 (0.0-71.5) | 1.5 (0.5-11.5) | 1.2 (0.0-71.5) | .432 |
| Protease inhibitors in last regimen | 64 (41.6%) | 6 (46.2%) | 58 (41.1%) | .774 |
| Daratumumab in last regimen | 30 (19.5%) | 0 (0.0%) | 30 (21.3%) | .074 |
| Isatuximab in last regimen | 45 (29.2%) | 2 (15.4%) | 43 (30.5%) | .348 |
| Alkylating agents in last regimen | 29 (18.8%) | 4 (30.8%) | 25 (17.7%) | .269 |
| Alkylating agents within 6 months before apheresis | 40 (26.1%) | 7 (53.8%) | 33 (23.4%) | .041† |
| History of RT | 65 (42.2%) | 9 (69.2%) | 56 (39.7%) | .075 |
| Total dose of RT (Gy) | 40 (20-174) | 38 (30-174) | 40 (20-160) | .454 |
| Time from last RT to apheresis, mo | 3.7 (0.0-133.9) | 1.9 (0.3-75.8) | 3.7 (0.0-133.9) | .910 |
| . | Total . | Failed . | Successful . | P value . |
|---|---|---|---|---|
| N = 154 . | n = 13 . | n = 141 . | ||
| Age at apheresis, y (range) | 63 (36-76) | 58 (44-71) | 63 (36-76) | .116 |
| Sex | 1.000 | |||
| Male | 86 (55.8%) | 7 (53.8%) | 79 (56.0%) | |
| Female | 68 (44.2%) | 6 (46.2%) | 62 (44.0%) | |
| M protein subclass | .468 | |||
| IgG | 80 (51.9%) | 7 (53.8%) | 73 (51.8%) | |
| IgA | 31 (20.1%) | 1 (7.7%) | 30 (21.3%) | |
| BJP | 41 (26.6%) | 5 (38.5%) | 36 (25.5%) | |
| Nonsecreting | 1 (0.6%) | 0 (0.0%) | 1 (0.7%) | |
| ISS at diagnosis | .581 | |||
| I | 41 (26.6%) | 2 (15.4%) | 39 (27.7%) | |
| II | 52 (33.8%) | 5 (38.5%) | 47 (33.3%) | |
| III | 43 (27.9%) | 6 (46.2%) | 37 (26.2%) | |
| Deletion 17p at diagnosis∗ | 26 (16.9%) | 5 (38.5%) | 21 (14.9%) | .031† |
| t(4;14) (IGH-FGFR3) at diagnosis∗ | 27 (17.5%) | 2 (15.4%) | 25 (17.7%) | 1.000 |
| t(14;16) (IGH-MAF) at diagnosis∗ | 5 (3.2%) | 0 (0.0%) | 5 (3.5%) | 1.000 |
| Gain 1q at diagnosis∗ | 28 (18.2%) | 4 (30.8%) | 24 (17.0%) | .234 |
| Disease status at apheresis | .073 | |||
| CR | 1 (0.6%) | 1 (7.7%) | 0 (0.0%) | |
| PR | 20 (13.0%) | 1 (7.7%) | 19 (13.5%) | |
| SD | 22 (14.3%) | 1 (7.7%) | 21 (14.9%) | |
| PD | 101 (65.6%) | 8 (61.5%) | 93 (66.0%) | |
| Time from diagnosis to apheresis, mo | 74.7 (8.2-364.7) | 77.5 (23.7-139.0) | 74.3 (8.2-364.7) | .637 |
| Number of chemotherapy lines before apheresis | 6 (2-13) | 6 (4-12) | 5 (2-13) | .008† |
| Time from last chemotherapy to apheresis, d | 35 (5-770) | 45 (18-770) | 34 (5-676) | .213 |
| History of ASCT | .442 | |||
| No | 23 (14.9%) | 1 (7.7%) | 22 (15.6%) | |
| Once | 96 (62.3%) | 7 (53.8%) | 89 (63.1%) | |
| ≥2 | 35 (22.7%) | 5 (38.5%) | 30 (21.3%) | |
| Time from last ASCT to apheresis, mo | 48.7 (2.4-178.4) | 23.2 (7.2-125.1) | 53.2 (2.4-178.4) | .200 |
| IMiDs in last regimen | 85 (55.2%) | 9 (69.2%) | 76 (53.9%) | .386 |
| Time from last IMiDs to apheresis, mo | 1.2 (0.0-71.5) | 1.5 (0.5-11.5) | 1.2 (0.0-71.5) | .432 |
| Protease inhibitors in last regimen | 64 (41.6%) | 6 (46.2%) | 58 (41.1%) | .774 |
| Daratumumab in last regimen | 30 (19.5%) | 0 (0.0%) | 30 (21.3%) | .074 |
| Isatuximab in last regimen | 45 (29.2%) | 2 (15.4%) | 43 (30.5%) | .348 |
| Alkylating agents in last regimen | 29 (18.8%) | 4 (30.8%) | 25 (17.7%) | .269 |
| Alkylating agents within 6 months before apheresis | 40 (26.1%) | 7 (53.8%) | 33 (23.4%) | .041† |
| History of RT | 65 (42.2%) | 9 (69.2%) | 56 (39.7%) | .075 |
| Total dose of RT (Gy) | 40 (20-174) | 38 (30-174) | 40 (20-160) | .454 |
| Time from last RT to apheresis, mo | 3.7 (0.0-133.9) | 1.9 (0.3-75.8) | 3.7 (0.0-133.9) | .910 |
ASCT, autologous stem cell transplantation; BJP, Bence-Johns proteins; IMiDs, immunomodulatory drugs; RT, radiation therapy; SD, stable disease.
Number of cases without available data in karyotyping is as follows: 48 (failed, 5; successful 43) for 17p deletion, 46 (failed, 4; successful 42) for t(4;14), 49 (failed, 4; successful, 45) for t(14;16), and 62 (failed, 6; successful, 56) for Gain 1q.
indicates P < .05.